A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date21/04/21 → 31/12/25

Keywords

  • Melanoma
  • Immunotherapy
  • Clinical trial